Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

by | May 22, 2026 | Clinical Trials | 0 comments

​ Conditions: Advanced HR+/HER2- Breast Cancer

Interventions: Drug: IEV407; Drug: Fulvestrant; Drug: Letrozole

Sponsors: Novartis Pharmaceuticals

Not yet recruiting Conditions: Advanced HR+/HER2- Breast Cancer
Interventions: Drug: IEV407; Drug: Fulvestrant; Drug: Letrozole
Sponsors: Novartis Pharmaceuticals
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *